SEGMENT REPORTING - Schedule of Reconciliation of Reported Revenues to Net (Loss) Income Under Significant Expense Principle (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Cost of goods sold	$ 1,256
Selling, general and administrative
Selling, general and administrative	145,732	$ 69,135	$ 43,628
Total operating expenses	250,726	194,181	139,146
Loss from operations	(173,732)	(193,944)	(138,550)
Net loss	(174,572)	(184,127)	(141,901)
Operating Segments
Revenues [Abstract]
Total revenues	77,000	200
Operating expenses:
Cost of goods sold	1,300
Selling, general and administrative
Other segment expenses	83,300	49,400
Total operating expenses	250,700	194,200
Loss from operations	(173,700)	(193,900)
Total interest and other income (expense)	(900)	9,800
Net loss	(174,600)	(184,100)
Product Revenue, Net
Revenues [Abstract]
Total revenues	76,495	0	$ 0
Product Revenue, Net | Operating Segments
Revenues [Abstract]
Total revenues	76,500
Royalties | Operating Segments
Revenues [Abstract]
Total revenues	500	200
Research and Clinical Expenses | Operating Segments
Research and development
Research and Development Expense	67,900	74,900
Chemistry, Manufacturing, and Control Expenses | Operating Segments
Research and development
Research and Development Expense	26,200	42,500
Commercial Expenses | Operating Segments
Selling, general and administrative
Selling, general and administrative	$ 72,000	$ 27,400